Monte Rosa Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GLUE Nasdaq 2830 www.monterosatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monte Rosa Therapeutics, Inc.

Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Jan 10th, 2026 8:12 am
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Jan 8th, 2026 8:49 pm
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Jan 8th, 2026 9:09 am
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - Jan 8th, 2026 6:55 am
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Jan 7th, 2026 2:01 pm
Top Midday Gainers - Jan 7th, 2026 12:44 pm
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why - Jan 7th, 2026 10:00 am
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - Jan 7th, 2026 5:00 am
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - Jan 6th, 2026 2:05 pm
Assessing Monte Rosa Therapeutics After Its 162.4% Surge and DCF Implied Upside in 2025 - Dec 17th, 2025 7:12 am
Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 - Dec 17th, 2025 5:11 am
Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High - Dec 16th, 2025 2:21 pm
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - Dec 16th, 2025 5:00 am
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - Dec 15th, 2025 2:01 pm
Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Nov 27th, 2025 6:09 am
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases - Nov 8th, 2025 9:30 am
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 6:30 am
Monte Rosa Therapeutics: Q3 Earnings Snapshot - Nov 6th, 2025 5:34 am
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates - Nov 6th, 2025 5:00 am
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates - Nov 4th, 2025 3:10 pm